Donanemab was found to slow "clinical decline" by up to 35%, allowing people with the disease to continue performing day-to-day tasks such as shopping, housekeeping, managing their finances and taking medication.
This is the third (actually second) new Alzheimer’s drug of the last 3 or so years.
Aducanumab - The first one, and possibly the most useless of them. The newest studies say reduces degradation by 2%
Lecanemab - The second, reduces degradation by 27%
Donanemab - This newest drug, reduces degradation by 35%
All three are based on the same mechanisms, so I don’t know if you could double-dip on medications.
Even if you could, would you want to double dip into your grandchildren’s savings and increase risk of ARIA (major risk of brain bleeds) all for a guarantee you’re going to die early and with dementia anyway?
This is the third (actually second) new Alzheimer’s drug of the last 3 or so years.
Aducanumab - The first one, and possibly the most useless of them. The newest studies say reduces degradation by 2%
Lecanemab - The second, reduces degradation by 27%
Donanemab - This newest drug, reduces degradation by 35%
All three are based on the same mechanisms, so I don’t know if you could double-dip on medications.
Even if you could, would you want to double dip into your grandchildren’s savings and increase risk of ARIA (major risk of brain bleeds) all for a guarantee you’re going to die early and with dementia anyway?